Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Yong-Mei Yin

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).

B. Lan, Ye-Hui Shi, Xi-Ying Shao et al. · 0 citations
Review Sep 2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov...

Jian Zhang, Q. Ouyang, Qing-Yuan Zhang et al. · 0 citations
Open access Aug 2026

A glucose metabolism-targeted nanoplatform amplifies disulfidptosis-associated immunogenic cell death in triple-negative breast cancer

Disulfidptosis is a metabolism-dependent form of cell death driven by disulfide stress that induces actin cytoskeletal collapse in SLC7A11-high cells under glucose deprivation. However, strategies to therapeutically exploit this vulnerability remain underdeveloped. Given the high dependence of triple-negative breast ca...

Jia-Lin Xu, Yanting Sun, Bin Huang et al. · 0 citations
Open access Sep 2026

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study

Sacituzumab tirumotecan (sac-TMT) is a novel anti-trophoblast cell-surface antigen 2 antibody-drug conjugate and has been approved for second-line and subsequent treatment of metastatic triple-negative breast cancer (TNBC) in China. This post-hoc exploratory study aims to further characterize the safety profile of sac-...

Ying Fan, Q. Ouyang, Yong-Mei Yin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.